Full Text:

 

영남의대학술지 Vol.24_No.2 Suppl. P.S108-117, Dec. 2007

Review

Ketamine: 통증관리에서 재조명된 Ketamine의 역할

Ketamine: Refocused Role of Ketamine in Pain Management

송선옥
영남대학교 의과대학 마취통증의학교실
책임저자:송선옥, 대구광역시 남구 대명동 317-1, 영남대학교 의과대학 마취통증의학교실
Tel: (053)-620-3365, Fax: (053)-626-5275
E-mail: sosong@med.yu.ac.kr

December 30, 2007

Abstract

Ketamine has used as a dissociative anesthetics from 40 years ago. Its mechanism of action is an antagonism of the N-methyl-D-aspartate (NMDA) receptors, which has an important role into the central sensitization during pain states. The role of ketamine, in lower sub-anesthetic doses, has recently gained increasing interest in pain management. There are considerable numbers of trials to use ketamine in acute or chronic pain states. Recently, Hocking et al. summarized their recent reviews of the evidence concerning ketamine’s clinical use on PAIN: Clinical Updates. In this review, the author introduce their summery with personal experience. Based on their summary, the primary role of ketamine in such sub- anesthetic doses is as an ‘anti-hyperalgesic’, ‘anti-allodynic’ or ‘tolerance-protective’ agent rather than as a primarily ‘analgesic’. However, to support the evidence-based clinical guideline using a ketamine in pain management, there will be needed numerous high-quality studies that access both immediate and long-term outcomes.

Key Words: Ketamine, NMDA antagonist, Pain management.

References

1. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003 Oct;97(4):1108-16.

2. Hirota K, Lamberta DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 1996 Oct;77(4):441-4.

3. Yamamura T, Kimura T, Furukawa K. Effects of halothane, thiamylal, and ketamine on central sympathetic and vagal tone. Anesth Analg 1983 Feb;62(2):129-34.

4. 조영우, 송선옥, 안동국, 이재용. 흰쥐 포르말린 통증행동으로 평가한 ketamine의 말초제통효과. 대한마취과학회지 2007 Sep;53(3):361-7.

5. Hocking G, Visser EJ, Schug SA, Cousins MJ. Ketamine: does life begin at 40. Pain: Clinical Updates 2007;XV(3):1-6.

6. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003 Dec;97(6):1730-9.

7. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother 2006 Aug;60(7):341-8. Epub 2006 Jul 5.

8. Mather LE, Edwards SR. Chirality in anaes- thesia: ropivacaine, ketamine and thiopentone. Curr Opin Anaesthesiol 1998 Aug;11(4):383-90.

9. Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995 Dec;77(6):355-9.

10. Scheller M, Bufler J, Hertle I, Schneck HJ, Franke C, Kochs E. Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. Anesth Analg 1996 Oct;83(4):830-6.

11. Ikonomidow C, Bosch F, Miksa M, Bittigau P, Vckler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegene- ration in the developing brain. Science 1999 Jan 1;283(5398):70-4.

12. Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesth Analg 2007 Mar;104(3):509-20.

13. South S, Smith MT. Analgesic tolerance to opioids. Pain: Clinical Updates 2001:IX(5);1-9.

14. Tao YX, Rumbaugh G, Wang GD, Petralia RS, Zhao C, Kauer FW, et al. Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J Neurosci 2003 Jul 30;23(17):6703-12.

15. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997 Aug 20;333(1):99-104.

16. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999 May; 81(1-2):85-93.

17. Clements JA, Nimmo WS, Grant IS. Bioavai- lability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982 May;71(5):539-42.

18. Gammaitoni A, Gallagher RM, Welz-Bosna M. Topical ketamine gel: possible role in treating neuropathic pain. Pain Med 2000 Mar;1(1): 97-100.

19. Bell RF, Dahl JB; Moore RA; Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006;1: CD004603.

20. Bell RF, Dahl JB, Moore RA, Kalso E. Peri- operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 2005 Nov;49(10):1405-28.

21. Elia N, Tramr MR. Ketamine and postoperative pain: a quantitative systematic review of randomized trials. Pain 2005 Jan;113(1-2):61-70.

22. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004 Aug;99(2):482-95.

23. Azevedo VM, Lauretti GR, Pereira NL, Reis MP. Transdermal ketamine as an adjuvant for postoperative analgesia after abdominal gyne- cological surgery using lidocaine epidural blockade. Anesth Analg 2000 Dec;91(6):1479-82.

24. Hayes C, Armstrong-Brown A, Burstal R. Perioperative intravenous ketamine infusion for the prevention of persistent post-amputation pain: a randomized, controlled trial. Anaesth Intensive Care 2004 Jun;32(3):330-8.

25. Migita RT, Klein EJ, Garrison MM. Sedation and analgesia for pediatric fracture reduction in the emergency department: a systematic review. Arch Pediatr Adolesc Med 2006 Jan; 160(1):46-51.

26. Tan PH, Cheng JT, Kuo CH, Tseng FJ, Chung HC, Wu JI, et al. Preincisional subcutaneous infiltration of ketamine suppresses postoperative pain after circumcision surgery. Clin J Pain 2007 Mar-Apr;23(3):214-8.

27. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005 Dec 5;118(3):289-305. Epub 2005 Oct 6.

28. Eide PK, Jrum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994 Sep;58(3):347-54.

29. Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995 May;61(2): 221-8.

30. Hempenstall K. A cost-effectiveness comparison of drugs for PHN. ProS Med 2005:2:e164.

31. Schley M, Topfner S, Wiech K, Schaller HE, Konrad CJ, Schmelz M, et al. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Pain 1995 May;61(2): 221-8.

32. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004 Mar;108(1-2):17-27.

33. Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383]. BMC Anesthesiol 2005 Apr;5(1):2.

34. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000 Apr;95(4): 575-90.

35. Schnenberg M, Reichwald U, Domes G, Badke A, Hautzinger M. Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology (Berl) 2005 Nov;182(3):420-5. Epub 2005 Oct 19.